Chemotherapy and radiotherapy causing radiation myelopathy: What is to blame? [3]

Clinical Oncology

Volumn 18, Issue 1, 2006, Pages 86-

  Walther, J ^a   Sivabalasingham, S ^a   Plowman, P N ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BUSULFAN; MELPHALAN;

ADOLESCENT; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CERVICAL SPINE; CLINICAL PROTOCOL; DRUG MEGADOSE; HUMAN; LETTER; MALE; NECK CANCER; PRIORITY JOURNAL; SPINAL CORD DISEASE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BUSULFAN; HUMANS; MALE; MELPHALAN; RADIATION INJURIES; RADIOTHERAPY; SPINAL CORD DISEASES;

EID: 30344453119     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2005.08.005     Document Type: Letter

References (4)

1. B.M. Seddon A.M. Cassoni M.J. Galloway et al. Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: A review of the literature and implications for practice Clin Oncol 17 2005 385-390
2. T.L. Phillips Radiation drug interactions in the treatment of cancer 1980 Wiley New York 175-200
3. G. Vassal O. Hartman J.L. Harbrand et al. Radiation sensitisation after bulsulphan Lancet 1 1987 571
4. S.J. Kellie P.N. Plowman J.S. Malpas Radiation recall and radiosensitisation with alkylating agents Lancet 1 1987 1149-1150